23Feb2015 Who Is Poised To Go Public in 2015, and Who Isn’t? /Luke Timmerman/2/All, Drugs, Finance, Strategy, The Edge, Venture Capital23 Feb 2015 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.